Product data sheet

MedKoo Cat#: 406301 Name: L-744832 CAS: 160141-09-3 Chemical Formula: $C_{26}H_{45}N_3O_6S_2$ Exact Mass: 559.2750 Molecular Weight: 559.782	
Product supplied as:	Powder
Purity (by HPLC):	≥ 98%
Shipping conditions	Ambient temperature
Storage conditions:	Powder: -20°C 3 years; 4°C 2 years.
	In solvent: -80°C 3 months; -20°C 2 weeks.

1. Product description:
L-744832, also known as L-744,832, is a potent Farnesyltransferase inhibitor with potential anticancer activity.

2. CoA, QC data, SDS, and handling instruction
SDS and handling instruction, CoA with copies of QC data (NMR, HPLC and MS analytical spectra) can be downloaded from the product web page under "QC And Documents" section. Note: copies of analytical spectra may not be available if the product is being supplied by MedKoo partners. Whether the product was made by MedKoo or provided by its partners, the quality is 100% guaranteed.

3. Solubility data

Solvent	Max Conc. mg/mL	Max Conc. mM
TBD	TBD	TBD

4. Stock solution preparation table:

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.79 mL	8.93 mL	17.86 mL
5 mM	0.36 mL	1.79 mL	3.57 mL
10 mM	0.18 mL	0.89 mL	1.79 mL
50 mM	0.04 mL	0.18 mL	0.36 mL

5. Molarity Calculator, Reconstitution Calculator, Dilution Calculator
Please refer the product web page under section of "Calculator"

6. Recommended literature which reported protocols for in vitro and in vivo study
In vitro study

1. Kavgaci H, Ozdemir F, Ovali E, Yavuz A, Yavuz M, Aydin F. Effect of the farnesyl transferase inhibitor L-744,832 on the colon cancer cell line DLD-1 and its combined use with radiation and 5-FU. Chemotherapy. 2005 Oct;51(6):319-23. doi: 10.1159/000088954. Epub 2005 Oct 13. PMID: 16224182.
2. Kopec M, Strusinska K, Legat M, Makowski M, Jakobisiak M, Golab J. Potentiated antitumor effects of a combination therapy with a farnesyltransferase inhibitor L-744,832 and butyrate in vitro. Oncol Rep. 2004 May;11(5):1127-31. PMID: 15069557.

In vivo study

1. Gaylo AE, Laux KS, Batzel EJ, Berg ME, Field KA. Delayed rejection of MHC class II-disparate skin allografts in mice treated with farnesyltransferase inhibitors. Transpl Immunol. 2009 Jan;20(3):163-70. doi: 10.1016/j.trim.2008.09.011. Epub 2008 Oct 18. PMID: 18930822; PMCID: PMC7369389.
2. Field KA, Charoenthongtrakul S, Bishop JM, Refaeli Y. Farnesyl transferase inhibitors induce extended remissions in transgenic mice with mature B cell lymphomas. Mol Cancer. 2008 May 19;7:39. doi: 10.1186/1476-4598-7-39. PMID: 18489761; PMCID: PMC2409375.

7. Bioactivity
Biological target:
L-744832, also known as L-744,832, is a potent Farnesyltransferase inhibitor with potential anticancer activity.

Product data sheet

In vitro activity

Administration of L-744,832, neither alone nor its combination with 5-FU and radiation, affected the number of DLD-1 cells and apoptosis rates. Regarding its effects on the cell cycle, L-744,832 was shown to lead to G(0)/G(1) and G(2)/M accumulation in a dose-dependent manner when administered alone. However, in combination with 5-FU, only a G(0)/G(1) accumulation was observed.

Reference: Chemotherapy. 2005 Oct;51(6):319-23. https://pubmed.ncbi.nlm.nih.gov/16224182/

In vivo activity

In syngeneic mice transplanted with the transgenic lymphoma cells, L-744,832 treatment prevented the growth of the tumor cells and the morbidity associated with the resulting lymphoma progression. Tumors that arose from transplantation of the lymphoma cells regressed with as little as three days of treatment with L-744,832 or SCH66336. Treatment of these established lymphomas with L-744,832 for seven days led to long-term remission of the disease in approximately 25% of animals.

Reference: Mol Cancer. 2008 May 19;7:39. https://pubmed.ncbi.nlm.nih.gov/18489761/

Note: The information listed here was extracted from literature. MedKoo has not independently retested and confirmed the accuracy of these methods. Customer should use it just for a reference only.